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Dear Editor,
Primary plasma cell leukemia (pPCL) is the rarest and
most aggressive entity within the spectrum of plasma cell
dyscrasias, accounting for nearly 2% of all plasma cell
dyscrasias1. Outcomes in pPCL have generally been grim
with a median overall survival (OS) of <12 months2–4.
Although currently there is a paucity of data on outcome
in pPCL—which are mostly derived from retrospective
studies—these data provided hints that the introduction
of autologous stem cell transplantation (autoSCT) as well
as proteasome-inhibitor (PI)-based and immunomodula-
tory (IMID)-based therapies have benefits for patients
with pPCL5–8. Indeed, the most far-reaching population-
based study—which included 445 pPCL patients diag-
nosed in the US during 1973–2009—demonstrated that
survival in pPCL improved notably since 2006, especially
for elderly patients4. This improvement was likely a
consequence of the availability of PI-based and IMiD-
based therapies for first-line treatment in the US from
2006 onwards. However, the improvement could not be
directly linked to changing treatment practices, as infor-
mation on treatment lacked in that study.
Given the scarcity of clinical and population-based
studies in pPCL, we conducted a population-based study
to assess trends in first-line therapy and survival among
patients with pPCL diagnosed during a 30-year period in
the Netherlands.
We identified all pPCL patients diagnosed between 1989
and 2018 from the nationwide Netherlands Cancer Reg-
istry (NCR), which was founded in 19899,10. The primary
endpoint was OS, defined as the time from diagnosis until
death from any cause. Patients alive were censored on
February 1, 2020. The log-rank test was used to test for
differences between survival distributions. Multivariable
Cox regression was applied to estimate the adjusted risk
of mortality. Information on primary therapy was avail-
able for each patient in the NCR. Calendar period analyses
(1989–2000, 2001–2007, and 2008–2018) were conducted
to assess trends in primary therapy and OS according to
age at diagnosis (≤65 and ≥66 years). The calendar periods
were defined accordingly to changing treatment practices
in multiple myeloma (MM) in the Netherlands. The full
methods of our study are provided in the Supplemental.
The Privacy Review Board of the NCR approved the use of
anonymous data for this study.
The baseline characteristics of 226 patients with pPCL
(median age, 66 years; range, 34–91 years; 52% males)
included in this study are presented in Supplemental
Table 1. One patient diagnosed at autopsy was excluded.
As shown in Fig. 1A, first-line treatment without SCT
was commonly applied among patients aged ≤65 years in
the periods 1989–2000 (65%) and 2001–2007 (59%).
Thereafter, the incorporation of SCT into the first-line
treatment increased markedly, namely from 23 to 60%
between 1989–2000 and 2008–2018 (P= 0.004). As for
patients aged ≥66 years, the proportion of patients who
did not start with treatment was higher as compared to
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patients aged ≤65 years (P < 0.001). Although the pro-
portion of patients aged ≥66 years not receiving therapy is
decreasing over time, a substantial number of these
patients still did not receive any therapy in the most
recent calendar period (28% and 49% in 2008–2018 and
1989–2007, respectively; P= 0.030). However, note-
worthy is the application of SCT among patients aged ≥66
in the most recent calendar period (8%; median age, 68
years; range, 66–69 years).
Detailed data on baseline characteristics of 71 patients
diagnosed in 2014–2018 are presented in Supplemental
Table 2. Of these patients, the majority was treated with a
PI-based regimen (58%; Fig. 1B). Twenty-two patients
received an SCT as part of their first-line treatment, of
whom nine received an autoSCT, eight the tandem of
autoSCT and allogeneic SCT, and five a tandem autoSCT.
Overall, the median follow-up was 9.3 months (range,
0.03–198.3 months), whereas it was 52.0 months (range,
13.7–198.3 months) for patients alive at the end of
follow-up. For all patients, median OS across the three
calendar periods was 8.8, 5.0, and 14.4 months, respectively
(P < 0.001; Supplemental Fig. 1). The corresponding esti-
mates for patients aged ≤65 and ≥66 were 12.2, 13.8, and
28.4 months (P= 0.002), and 2.0, 2.4, and 6.4 months (P=
0.009), respectively (Fig. 2). Although OS improved over
time, early mortality within 6 months after diagnosis
remained high over time for both age groups. Among
patients aged ≤65, the proportion of early mortality was
31%, 33%, and 25% for the three consecutive calendar per-
iods (P= 0.667). The corresponding proportions for
patients aged ≥66 years were 73%, 70%, and 49% (P= 0.067).
The projected OS at 6 months and 1, 2, and 5 years post-
diagnosis according to age at diagnosis and calendar period
of diagnosis are presented in Fig. 2.
When simultaneously adjusted for sex, age at diagnosis,
and calendar period of diagnosis, patients diagnosed
during 2008–2018 had a lower risk of mortality (adjusted






















1989-2000 2001-2007 2008-2018 1989-2000 2001-2007 2008-2018
First-line treatment without SCT First-line treatment with SCT No therapy
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Fig. 1 First-line treatment of patients with pPCL in the Netherlands. The absolute numbers of patients are depicted in the bars. A The first-line
treatment for patients diagnosed with pPCL between 1989 and 2018 according to age at diagnosis and calendar period of diagnosis. B The
information on the exact therapeutic regimen for diagnosed patients with pPCL between 2014 and 2018 according to age at diagnosis. Of note,
patients who received KRD were treated within the setting of a clinical trial. pPCL primary plasma cell leukemia, SCT stem cell transplantation,
bortezomib-dexamethasone (VD), VD with cyclophosphamide (VCD), VD with lenalidomide (VRD), VD with thalidomide (VTD), lenalidomide-
dexamethasone (RD), RD with carfilzomib (KRD), VD with doxorubicin (PAD), melphalan-prednisone (MP), and MP with bortezomib (MPV).
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0.42–0.84; P= 0.003), as compared to patients diagnosed
before 2007. Furthermore, patients aged ≥66 years had a
higher risk of mortality (adjusted HR, 2.19; 95% CI
1.63–2.94; P < 0.001), as compared to patients aged ≤65
years (Supplemental Table 3). However, when additionally
adjusted for first-line treatment, the prognostic effects of
calendar period and age lost statistical significance. This
finding suggests that the broader application of therapy,
especially the application of SCT, contributed to the
improved survival over time, and this was irrespective of
age (Supplemental Table 3).
In this comprehensive, nationwide, population-based
study, the survival of pPCL patients improved over time.
However, early mortality remains high, which is probably
related to both disease-related and therapy-related com-
plications. Our study is the first to directly link the
improvements in survival with changes in first-line ther-
apy over time. Collectively, patients with pPCL likely
benefited from the therapeutic advances achieved over the
past decades.
Our findings are mostly in keeping with a previous
population-based study conducted in the US during
1973–20094, and prospective and10 retrospective stu-
dies11,12, including a multicenter study conducted in
Greece during 2000–20165. However, in our study, the
median OS of patients aged ≥66 years diagnosed during
2008–2018 was lower, as compared to the median OS of
patients ≥66 years diagnosed during 2006–2009 in the US
—possibly due to a delay in the introduction of more
effective therapies in the Netherlands compared to the
US. The importance of novel agent-based regimens in
pPCL was also shown among 50 pPCL patients diagnosed
in Greece during 2000–20165. That study revealed that
OS was significantly higher among patients managed with
bortezomib-based regimens and autoSCT, as compared to
those managed with more conventional therapies. Fur-
thermore, our results compare less favorably with two
relatively small prospective trials, which are the only trials
published to date in pPCL7,8. These differences may be
related to the use of novel agent-based regimens in all
patients enrolled in these clinical trials, as compared to
only 58% of the patients diagnosed in 2014–2018 in our
study. Also, the selection of comparatively fit patients
fulfilling the strict inclusion criteria of trials—as com-
pared to the inclusion of all pPCL patients identified in
population-based registries—may result in differences
between the studies. Concerning stem cell transplanta-
tion, the OS in transplant-eligible pPCL patients in three
large retrospective series6,13,14 was superior, as compared
to the OS of pPCL patients aged ≤65 years diagnosed in
2014–2018 in our population-based study—of whom 63%
received autoSCT. However, it is unknown which pro-
portion of patients in the retrospective series6,13,14 was
planned to undergo autoSCT, but eventually did not
receive this treatment because of either early progression
or early death. This particular selection bias may lead to
an overestimation of the effectiveness of autoSCT in
pPCL. Taken together, the therapeutic advances achieved
in recent decades seem to gradually translate into tangible
benefits for pPCL patients at the population level.
Nevertheless, the specific design and conduct of pro-
spective intervention studies in pPCL across different
2001-2007 2008-20181989-2000














P for trendOS (in %) with 95% CI OS (in %) with 95% CI
6-months 69 (48-83) 67 (46-81) 75 (62-85) 0.424 27 (8-50) 30 (15-47) 51 (39-62) 0.036
1-year 54 (33-71) 56 (35-72) 61 (48-73) 0.442 13 (2-35) 23 (10-39) 46 (35-58) 0.008
2-year 15 (5-31) 33 (17-51) 51 (37-63) 0.009 13 (2-35) 3 (0.2-15) 28 (18-39) 0.007
5-year 4 (0.2-16) 26 (11-43) 37 (24-50) 0.003 7 (0.4-26) - 11 (4-21) -
Fig. 2 Overall survival (OS) of patients with pPCL in the Netherlands, 1989–2018. OS is stratified by calendar period of diagnosis and shown for
the following age categories: ≤65 years (left panel), and ≥66 years (right panel). The P-value of the log-rank test for trend is indicated in the Figure.
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lines of therapy are imperative to advance the evidence-
based management of pPCL. International collaboration
is needed to accomplish such trials.
The main strength of our study includes the use of a
nationwide population-based cancer registry with com-
prehensive data available on first-line treatment. There-
fore, changing treatment practices over time could be
assessed and directly linked to improvements in outcome.
Limitations of our study mainly pertain to the lack of
detailed information on first-line treatment throughout
most of the study period (i.e., 1989–2013) and potential
misclassification of pPCL as MM or vice versa, especially
in earlier periods. Despite these limitations, cancer regis-
tries remain the standard for cancer surveillance activities.
In summary, the population-level survival of pPCL
patients improved significantly over time. Notwithstand-
ing this encouraging finding, survival in pPCL remains
unsatisfactory, especially among the elderly. Therefore,
the design and conduct of forthcoming prospective
intervention studies for patients with pPCL are essential
to establish evidence-based treatment recommendations,
which, in turn, may further improve the outcome in this
patient population.
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